Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 51,611,501 |
|
|||||
| News | - | ||||||
| Day High | 0.195 | Low High |
|||||
| Day Low | 0.1356 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kintara Therapeutics Inc | KTRA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0155 | -9.81% | 0.1425 | 18:59:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.195 | 0.1356 | 0.195 | 0.1488 | 0.158 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 55,997 | 51,611,501 | US$ 0.1590624 | US$ 8,209,449 | - | 0.081 - 5.98 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:28 | 6 | US$ 0.1425 | USD |
Kintara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.86M | 39.04M | - | 0 | -15.02M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kintara Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/05/2024 | 12:09 | PR Newswire (US) | Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to.. |
| 4/03/2024 | 06:00 | PR Newswire (US) | Kintara Therapeutics and TuHURA Biosciences Enter into.. |
| 3/27/2024 | 08:00 | PR Newswire (US) | Kintara Therapeutics Announces Expansion of REM-001 Clinical.. |
| 2/27/2024 | 05:59 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/26/2024 | 06:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/22/2024 | 06:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/14/2024 | 15:07 | PR Newswire (US) | Kintara Therapeutics Announces Fiscal 2024 Second Quarter.. |
| 2/12/2024 | 08:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/12/2024 | 08:00 | PR Newswire (US) | Kintara Therapeutics Announces Initiation of REM-001.. |
| 12/18/2023 | 15:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/18/2023 | 15:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 12/15/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KTRA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1195 | 0.195 | 0.111 | 0.1382076 | 6,883,017 | 0.023 | 19.25% |
| 1 Month | 0.098 | 0.24 | 0.0925 | 0.1536399 | 17,385,585 | 0.0445 | 45.41% |
| 3 Months | 0.1262 | 0.24 | 0.081 | 0.1254428 | 14,359,220 | 0.0163 | 12.92% |
| 6 Months | 3.83 | 4.48 | 0.081 | 0.1442767 | 9,853,584 | -3.69 | -96.28% |
| 1 Year | 2.95 | 5.98 | 0.081 | 0.1840531 | 4,976,790 | -2.81 | -95.17% |
| 3 Years | 78.00 | 142.50 | 0.081 | 10.44 | 2,699,553 | -77.86 | -99.82% |
| 5 Years | 60.50 | 167.50 | 0.081 | 14.91 | 2,320,026 | -60.36 | -99.76% |
Kintara Therapeutics Description
| Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. |
